Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities\: Challenge or opportunity?
13
作者人数
13
被引次数
来源:Crossref,截至 2026-10-20
作者
- 1 Linlin Bo 第一作者
- 2 Yiqin Wang
- 3 Yifan Feng
- 4 Jingyi Zhou
- 5 Yuanyuan Liu
- 6 Yijiao He
- 7 Yuanhe Zhai
- 8 Yuan Fan
- 9 Xiaobo Zhang
- 10 Rong Zhou
- 11 Danhua Shen
- 12 Li Tian
- 13 Jianliu Wang
参考文献 共 25 条
- 1 Cancer incidence and mortality in China, 2022
- 2 Understanding risk factors for endometrial cancer in young women 10.1093/jnci/djae210
- 3 Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma 10.3802/jgo.2024.35.e42
- 4 Insulin resistance and metabolic syndrome increase the risk of relapse for fertility preserving treatment in atypical endometrial hyperplasia and early endometrial cancer patients
- 5 Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients 10.1016/j.ygyno.2015.09.078
- 6 Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis 10.1016/j.cgh.2020.11.038
- 7 2023 Chinese guideline for lipid management
- 8 Chinese expert consensus on fertility-preserving treatment for young women with early stage well differentiated endometrial cancer 10.1016/j.gocm.2020.10.002
- 9 Targeting Cancer metabolism plasticity with JX06 nanoparticles via inhibiting PDK1 combined with metformin for endometrial cancer patients with diabetes
- 10 Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort 10.1186/s12967-023-04671-w
- 11 Azelnidipine nanoparticles break calcium homeostasis and induce severe ER stress combined with medroxyprogesterone acetate for endometrial cancer therapy 10.1016/j.nantod.2022.101682
- 12 The role of oestrogen and oestrogen-calcium axis in endometrial carcinoma
- 13 Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment 10.1016/j.ygyno.2024.09.015
- 14 Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia 10.1136/ijgc-2022-003882
- 15 Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: A Korean Gynecologic-Oncology Group Study 10.3802/jgo.2019.30.e47
- 16 Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review 10.3802/jgo.2023.34.e49
- 17 A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial) 10.3802/jgo.2024.35.e106
- 18 The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches 10.1016/j.bbcan.2023.189000
- 19 Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial 10.1111/1471-0528.16108
- 20 Etiological relationship between lipid metabolism and endometrial carcinoma 10.1186/s12944-023-01868-2
- 21 Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line 10.1186/s12967-019-1814-6
- 22 DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial 10.1016/j.ygyno.2024.02.017
- 23 Estrogen-induced extracellular calcium influx promotes endometrial cancer progress by regulating lysosomal activity and mitochondrial ROS.
- 24 Calcium and TRPV4 promote metastasis by regulating cytoskeleton through the RhoA/ROCK1 pathway in endometrial cancer 10.1038/s41419-020-03181-7
- 25 Calcium and calcium-related proteins in endometrial cancer: opportunities for pharmacological intervention 10.7150/ijbs.68591
数据来源
- 论文信息:
- 中华医学期刊网、Crossref
- 作者名单:
- Crossref
- 被引次数:
- Crossref,截至 2026-10-20
- 参考文献:
- Crossref
论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。